Company intelligence / Profile preview
Archeus Technologies
Madison, Wisconsin, United Statesarcheustech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Archeus Technologies received FDA IND clearance for ART-101 (PSMA-targeting small molecule) for mCRPC, showing higher tumor uptake/retention and lower normal tissue toxicity compared to current PSMA agents; multiple Phase 1 trials to initiate in 2025 for ART-101 and ARC-706. Preclinical data for NM600 and ARC-706 suggest enhanced immune response and curative potential when combined with immunotherapy.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeRadiopharmaceutical
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Wisconsin Alumni Research Foundation (WARF)University of Wisconsin–Madison (UW–Madison)Isthmus Project (investment and commercialization support)
Beyond the preview
Go deeper on Archeus Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Archeus Technologies.